North Bud Farms Announces Creation of “1017” Distribution and Signing of a Letter of Intent to Acquire Cannabis Accessory Distributor and Product Developer Janey’s
Momentum Public Relations
Press Release: October 17, 2018
North Bud Farms Inc.(CSE: NBUD) (“NORTHBUD” or the “Company”) announces the creation of “1017” distribution and signing of a letter of intent to acquire Ontario cannabis store accessory distributor of Janey’s which operates as a subsidiary of Twelve Barrels Whiskey.
This Agreement provides that NORTHBUD will acquire ownership of assets related to Janey’s line of cannabis accessories and IP related to product development.
In exchange for these rights, Twelve Barrels Whiskey will receive 120,000 common shares of North Bud Farms at a deemed price of $0.40 per share.
NORTHBUD will provide the required capital investments to develop the proposed line of Janey’s products and may enter into revenue sharing agreements.
The companies intend to negotiate a definitive agreement within the next 30 days.
“This acquisition will provide a solid foundation for “1017” distribution,” said Ryan Brown, CEO and Founder of North Bud Farms Inc. “Janey’s brand was created as a platform for cannabis product development and distribution.”
Brown further stated, “With the acquisition of Janey’s brand NORTHBUD has secured an experienced product development and distribution partner with existing distribution into the Ontario Cannabis Store retail program.”
As per the terms of the Agreement, Cole Miller founder and sole owner of Janey’s brand and Twelve Barrels Whiskey will join the NORTHBUD team as product development manager.
“We are excited to have Cole lead this new division for both accessories and consumer product goods to be sold under our “1017” brand,” said Ryan Brown, CEO and Founder of North Bud Farms Inc.
“Our alcoholic beverages experience combined with NORTHBUD’s cannabis expertise and technology will allow our existing accessories brand to develop new products and expand into markets both domestically and abroad,” said Cole Miller, Founder of Janey’s.
Miller stated, “We are looking forward to working with NORTHBUD to further develop our line of cannabis-based beverages which are at a late stage in their development. As 1 of 10 accessories supplier to the Ontario Cannabis Store, we are well positioned to expand our product offering and gather consumer market data.”
About “1017” Brands
“1017” Brands has been established as a development and distribution platform for cannabis products and accessories. NORTHBUD intends to develop multiple products over a variety of product segments under the “1017” brand.
In August 2018 NORTHBUD successfully filed a trademark application for the use of the words and numbers “1017” as it relates to the global cannabis industry. The filing of this trademark gives NORTHBUD priority over the use of “1017” which we believe will become an iconic symbol in the Canadian cannabis industry.
“Branding will play an important role in establishing both product and company identity,” said Ryan Brown, CEO and Founder of North Bud Farms Inc. “October 17, 2018 represents a historic day in the history of Cannabis in Canada and NORTHBUD is proud to be able to carry that moniker moving forward. Over the next 12 months NORTHBUD intends to develop multiple consumer products to be sold under the “1017” brand.”
About Janey’s Inc.
Janey’s Inc. is a subsidiary of Twelve Barrels Whiskey Inc., an Ontario corporation. Janey’s is one of six approved Cannabis accessory suppliers to the Ontario cannabis store.
For more information visit: https://twelvebarrels.com/
About North Bud Farms Inc.
North Bud Farms Inc., through its wholly-owned subsidiary GrowPros MMP Inc. which was acquired in February 2018, is pursuing a license under the Access to Cannabis for Medical Purposes Regulations (ACMPR). North Bud Farms will be constructing a state-of-the-art purpose-built cannabis production facility located on 95 acres of Agricultural Land in Low, Quebec. North Bud Farms will be focused on Pharmaceutical and Food Grade cannabinoid production in preparation for the legalization of edibles and ingestible products scheduled for October 2019.
For more information visit: www.northbud.com
Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward- looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such risks and uncertainties include, among others, the risk factors included in North Bud Farms’ final long form prospectus dated August 21, 2018 which is available under the issuer’s SEDAR profile at www.sedar.com.
FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
North Bud Farms Inc.
Edward Miller
VP, IR & Communications
Office: (855) 628-3420 ext. 3
investors@northbud.com
- Published in Business, Life Sciences, Marijuana, Medical Marijuana, News Home, NorthBud
Sirona Biochem Announces Close of Financing and Extension of Convertible Notes
Momentum Public Relations
Press Release: October 17, 2018
Sirona Biochem Corp. (TSX-V: SBM) (Frankfurt: ZSB) (the “Company”) announced that it has closed a private placement (subject to TSX.V approval) in the amount of 7,095,100 units at $0.10 per unit for total gross proceeds of $709,510. Each unit consists of one common share and one transferable share purchase warrant. Each whole warrant is exercisable into one additional common share of the Company for a period of three years, from the date of issue, at a price of $0.18 per share.
The Company paid a total of $9,532 in finder’s fees in connection with the placement.
“We are very pleased that we have ongoing support from our existing shareholders as well as interest from new parties,” said Howard Verrico, CEO. “The funds will go toward the upcoming clinical trial, international partnering activities, paying off a portion of existing convertible notes, as well as general operating expenses.”
All securities issued under the placement are subject to statutory hold periods expiring on February 16, 2019.
The Company also announced that it extended $443,600 of the $665,360 convertible notes that matured August 31, 2018. Each Note will be extended for a 12 month term, convertible at the option of the holder into one common share of the company at a conversion price of $0.14 per share.
The Notes will bear interest at the rate of 12% per annum, payable quarterly, until the Notes are converted or repaid. The company will be entitled to repay the principal amount of the Notes, together with accrued and unpaid interest, at any time commencing four months after the date of issuance, subject to giving the holders prior notice thereof to permit holders to convert during the notice period. The Notes are unsecured and transferable, subject to resale restrictions under applicable securities laws and TSX Venture Exchange requirements.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, please contact:
Christopher Hopton, CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in Business, Life Sciences, News Home, Sirona Biochem
North Bud Farms Provides a Corporate Update
Momentum Public Relations
Press Release: October 16, 2018
North Bud Farms Inc.(CSE: NBUD) (“NORTHBUD” or the “Company”) is pleased to provide shareholders an update on our corporate activities.
Construction of Our Cannabis Production Facility in Low, Quebec:
NORTHBUD and its team have been hard at work finalizing some minor design changes to our proposed facility located on 95 acres of agricultural land in Low, Quebec. NORTHBUD has received a detailed timeline for construction from our builder, NGA Construction Inc., and is on schedule to have the facility completed and an evidence package submitted to Health Canada in Q1 2019. We are pleased to report the facility budget is on target.
All infrastructure implementation has been completed and physical facility construction will begin, October 17, 2018.
ACMPR Application:
As previously disclosed in our prospectus, NORTHBUD, through its wholly-owned subsidiary GrowPros MMP Inc. which was acquired from Tetra Bio-Pharma Inc. in February 2018, is pursuing a license under the Access to Cannabis for Medical Purposes Regulations (ACMPR). In this regard, NORTHBUD has engaged Cannabis Compliance Inc. to assist in the migration of the ACMPR application to the CLTS which goes into effect after the implementation of the Cannabis Act on October 17, 2018. NORTHBUD will be making amendments in order to take advantage of favourable changes that have been implemented under the Cannabis Act.
Key New Hires:
NORTHBUD is pleased to announce the hiring of Magda Farid who will serve as our head of Quality Assurance and Compliance. Ms. Farid previously served as head of quality assurance for HEXO Corp. (formerly known as The Hydropothecary Corporation), a licensed producer under the ACMPR, in addition to multiple roles as Quality Assurance Manager in the pharmaceutical industry with companies such as McKesson and Trillium Health Care Products Inc. Ms. Farid has a Bachelor of Science degree from the University of Ottawa with a double major in biochemistry and nutrition.
“NORTHBUD is very pleased to be able to bring on a quality assurance manager with experience in both the cannabis and pharmaceutical industries,” said Ryan Brown, CEO and Founder of North Bud Farms Inc. “This decision was made to bring in a new Quality Assurance Manager as we believe that a combination of experience in pharmaceutical and cannabis is critical for NORTHBUD to execute on its strategy to be a strategic supplier of Pharmaceutical and Food grade cannabis inputs. We are focused on strengthening our team to be prepared for Legalization 2.0 as well as exploring opportunities to accelerate our development and provide value to shareholders.”
About North Bud Farms Inc.
North Bud Farms Inc., through its wholly-owned subsidiary GrowPros MMP Inc. which was acquired in February 2018, is pursuing a license under the Access to Cannabis for Medical Purposes Regulations (ACMPR). North Bud Farms will be constructing a state-of-the-art purpose-built cannabis production facility located on 95 acres of Agricultural Land in Low, Quebec. North Bud Farms will be focused on Pharmaceutical and Food Grade cannabinoid production in preparation for the legalization of edibles and ingestible products scheduled for October 2019.
For more information visit: www.northbud.com
Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward- looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such risks and uncertainties include, among others, the risk factors included in North Bud Farms’ final long form prospectus dated August 21, 2018 which is available under the issuer’s SEDAR profile at www.sedar.com.
FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
North Bud Farms Inc.
Edward Miller
VP, IR & Communications
Office: (855) 628-3420 ext. 3
investors@northbud.com
- Published in Business, Life Sciences, Medical Marijuana, News Home
Next Green Wave Holdings Inc. announces proposed acquisition of Loud Seeds – a High Times Hall of Fame inductee
Momentum Public Relations
Press Release: October 16, 2018
Next Green Wave Holdings Inc. (CSE : NGW) (“Next Green Wave” or the “Company“), is pleased to announce that it has entered into a letter of intent (“LOI“) whereby the Company intends to acquire 100% of Loud Seeds, LLC (“Loud Seeds”) along with the Loud Seeds brand and all of its related assets (the “Transaction“). As consideration for the Transaction, Next Green Wave intends to distribute $2,000,000 in common shares of the Company to the shareholders of Loud Seeds. Completion of the Transaction is subject to the satisfaction of a number of conditions, including completion of due diligence by the Company, obtaining all required regulatory approvals.
Michael Jennings, CEO and Director of NGW, is a principle in Loud Seeds. The Transaction is therefore a related party transaction and will be subject to the requirements of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions. The Transaction was approved by all the independent directors.
Loud Seeds is a multiple cannabis cup winner for its seeds and clones, has flourished as innovators in developing premium quality cannabis products to meet the dynamic consumer demands. The principles over the past 20 years have developed a vast collection of award-winning strains and has been inducted into the High Times Hall of Fame and the Top 40 Seed Banks of all time.
KEY HIGHLIGHTS
- Loud Seeds brings an extensive catalogue of cannabis genetics into Next Green Wave accelerating its nursery and cultivation ability
- Loud Seeds is a six-time High Times Cannabis Cup winner
- Loud Seeds has been inducted into the High Times Hall of Fame and listed in the Top 40 Seed Banks of all time
James Load (Principle / Founder) of Loud Seeds: “We are excited to bring our extensive portfolio into Next Green Wave, who’s vision and innovative nursery and cultivation style will see our Loud Seeds genetic library go to the next level. Next Green Wave’s cannabis platform is exceptional and their vision to be a dominate force in California and other jurisdictions is exciting for Loud Seeds.”
Leigh Hughes, Executive Chairman of Next Green Wave:“Being able to bring one of the best seed banks in the world into our nursery continues to differentiate Next Green Wave from other cultivators. “We are excited to join an award-winning genetics portfolio with world-class breeding skills as the construction of our first facility nears completion and begins cultivation.”
ABOUT LOUD SEEDS, LLC
Loud Seeds was founded by Kenneth James Koskiniemi (aka: James Loud) and Michael Jennings (aka: Mike Seeds) who have been growing and breeding premium cannabis for over 20 years with a focus on organic growing. Over that time, Loud Seeds has developed a vast collection of cannabis strains and worked with some of the finest cultivators in the United States and Europe on innovative growing techniques and breeding projects.
Loud Seeds has been inducted into the High Times Hall of Fame and listed in the Top 40 Seed Banks of all time. Being covered in the press by The Million Dollar Grow Room, America’s Next Pot Kings and the Top Ten Strains of the Year, the Loud Seeds brand is one of the more recognized seed brands in California. Loud Seeds have breeding methods that have been developed for over 20 years and are specialists in creating, launching and marketing new strains based on consumer demand. Loud Seeds has also built a strong distribution list in California along with relationships with many other well-known cultivators and breeding partners.
ABOUT NEXT GREEN WAVE HOLDINGS INC.
Headquartered in Western Canada, Next Green Wave is a vertically integrated premium medicinal and recreational cannabis company operating in California, one of the world’s largest cannabis markets. Led by award-winning cannabis industry veteran Michael Jennings and an industry innovator specializing in premium cannabis products. The Company has plans to build four facilities centrally located on 15.5 acres of land in Coalinga, California allowing for state-wide reach across the lucrative California market.
For information on Next Green Wave please visit www.nextgreenwave.com/investors. For copies of news releases and all company materials please refer to SEDAR (www.sedar.com). For all investor relations information, please refer to www.nextgreenwave.com/investors or contact IR@nextgreenwave.com or +1 778-589-5054.
- Published in Business, Life Sciences, Medical Marijuana, News Home
Tetra Bio-Pharma Names Dr. Guy Chamberland as Chief Executive Officer and Chief Scientific Officer
Momentum Public Relations
Press Release: October 15, 2018
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced the permanent appointment of Guy Chamberland, Ph.D., as CEO and CSO having most recently held the position of CEO in an interim capacity. Dr. Chamberland has more than 23 years’ experience in the development of new drugs in the North American pharmaceutical industry. He worked for more than 10 years as an executive with several biopharmaceutical companies and was a member of the investment committee of a venture capital fund for 7 years. Since joining Tetra Bio-Pharma in June 2016, Dr. Chamberland and his team have accomplished numerous milestones. These include having:
- Built a solid pipeline of five cannabinoid-based therapeutics using a variety of delivery mechanisms focused on a number of different disease indications many representing billion dollar markets;
- Developed an innovative regulatory strategy for each of these products to maximize approval success – thereby rapidly building shareholder value;
- Taking Tetra’s lead product PPP001 from concept to Phase 3 in less than two years and at 20 percent of the cost of a typical bio-pharma company;
- Taken the first smokable product into a Phase I and Phase III clinical trial;
- Structured company activities in three distinct commercial divisions: bio-pharma, natural health and veterinary medicine;
- Negotiated a major supply agreement with a well-established player in the natural health products market; and
- Increased the company’s share price more than 50% since assuming the role of interim CEO.
“We are extremely pleased with the progress that Guy has made since joining the company in 2016 and equally impressed with his accomplishments since being named interim CEO,” stated Tetra Bio-Pharma’s Chairman of the Board, Bill Cheliak. “It is for these reasons that the Board unanimously voted to permanently appoint Guy to the position of CEO, along with his role as Chief Scientific Officer. We look forward to seeing Guy and his team build on the tremendous momentum they have generated thus far and continue to increase shareholder value.”
“I am greatly honored by this nomination as well as by the confidence that the Board of Directors has shown in me,” said Dr. Chamberland. “As the CEO of Tetra Bio-Pharma I am excited and deeply committed to lead our team through the next stages of development. We are confident that our innovative pipeline of cannabis and cannabinoid products will play an important role in improving the lives of patients suffering from a range of chronic and acute pain conditions and have a significant impact in opioid sparing and/or replacement. It is evident that the pharmaceutical pathway that we are championing in order to establish the scientific evidence that regulators, the medical community and payers in Canada, the United States and Europe require in order to approve cannabis-based products is becoming better understood and increasingly welcomed. Our robust activity in the natural health sector further demonstrates our capacity for innovation.”
About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
- Published in Business, Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
MedX Health closes first tranche of placement
Momentum Public Relations
Press Release: October 11, 2018
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announces that, pursuant to a non-brokered Private Placement Offering (the “Placement Offering”), it has completed an initial Closing of 2,106,250 Units, to raise $337,000 from accredited investors. The Company is planning to raise up to $2.5 million by issuance of up to 15,625,000 Units from the Placement Offering. Each Unit, priced at $0.16, comprises one fully paid common share and one share purchase warrant; each warrant entitles the holder to purchase one additional share at a price of $0.35 during the period up to three years from the closing date of the placement. The securities issued as a result of the Placement Offering will be restricted from trading for four months following each Closing. The Placement Offering is still open to subscribers, and further subscriptions may be accepted for further Closings. This Closing, and any further Closing of the Placement Offering, is subject to all relevant regulatory and other consents and approvals, including acceptance by the TSX Venture Exchange.
Following this Closing, MedX has 133,916,401 common shares issued and outstanding.
About MedX
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.
This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company’s limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company’s projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181011005958/en/
Contacts:
MedX Health Corp
Scott Spearn, 905-670-4428 ext 229
President and CEO
or
Media Relations
Deborah Thompson, 416-918-9551
dthompson@medxhealth.com
- Published in Business, Life Sciences, MedX Health Corp., News Home, Technology
AREV Brands International Announces Mike Withrow as CEO
Momentum Public Relations
Press Release: October 11, 2018
AREV Brands International Ltd. (” AREV ” or the “Company”) ( CSE – AREV ), is pleased to announce Mike Withrow will act as the Company’s Chief Executive Officer (“CEO”), effective October 11, 2018.
Effective October 11, 2018 Stephane Maher, has resigned as CEO of the Company, in order to focus all his efforts on being the Business Development Manager, Quebec. Mr. Maher will be executing the Company’s tactical direction in Quebec, and review of strategic opportunities presented to the Company within this territory and the surrounding areas.
Scott Davis, AREV CFO, comments “It is great to have Mr. Withrow come on in the capacity of CEO to see the Company through to the next phase. We have been so fortunate to not only have his skills and expertise to guide us, but Mr. Withrow has also agreed to work for $1 a year, until such time as the Company is revenue positive.”
The Company wishes to thank Mr. Maher for all his contributions as an Officer of the Company and looks forward to continuing to work with Mr. Maher in this new capacity.
For further information, contact Mike Withrow, Director at mike@arevnutrition.com
On behalf of the Board,
Mike Withrow
Director
About AREV Brands International
AREV Brands International (“AREV”) produces and delivers functional ingredients from its world-class extraction systems. AREV is revolutionizing the current delivery method of coconut oil, whey protein and nutrients through emulsification. These premium ingredients and products are targeted for the natural health, medical, functional food, nutraceutical, sport nutrition and bioceutical markets. AREV is also working with Pharmacy and Dispensary operators with an innovative emulsified base formula to disperse Cannabis oil extracts from specific selected genetic Cannabis strains that address 5 areas of health including Anxiety, Pain Management, Insomnia, Central Nervous System Disorders & Libido.
- Published in AREV Nutrition Sciences, Business, Medical Marijuana, News Home
Sirona Biochem to Present at the 2018 Arctic Circle Assembly
Momentum Public Relations
Press Release: October 11, 2018
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (the “Company”) announced today that Chief Scientific Officer, Dr. Geraldine Deliencourt-Godefroy will attend and present at the Arctic Circle Assembly. This conference will take place October 19th – 21st at the Harpa Conference Center in Reykjavik, Iceland.
The Arctic Circle Assembly is the largest international gathering on the future of the Arctic. As described by the organizers, this annual event invites attendees from 60 countries, ranging from heads of states and governments, ministers, members of parliament, officials, experts, scientists, entrepreneurs, business leaders, indigenous representatives, environmentalists, students, activists and others from the growing international community of partners and participants interested in the future of the Arctic. The Assembly covers a wide variety of topics designed in collaboration with partner organizations.
Dr. Deliencourt-Godefroy will be presenting in the Science and Traditional Knowledge Program. She’ll be discussing her work on glycoproteins based on arctic fish, a project she has been passionate about since her career began. In her post-doctoral research, Dr. Deliencourt-Godefroy was inspired by the naturally occurring antifreeze glycoproteins in the bloodstream of some fish that allow them to survive sub-zero temperatures. She has since developed a novel, patented family of compounds with a unique ability to resist stress, that are suitable for numerous commercial applications.
For over fifteen years, Dr. Deliencourt-Godefroy has continued to receive recognition for her innovative research and development within Europe, especially by the French Government. Prior to the Arctic Circle Assembly, Dr. Deliencourt-Godefroy will be attending Cosmetic 360 in Paris, France. At this global cosmetic trade fair, Sirona will be attending pre-arranged meetings as well as continuing to build networks with top industry representatives in cosmetics.
About the Arctic Circle Assembly
Established in 2013, the Arctic Circle Assembly is organized by the Arctic Circle, a non-profit organization creating a dialogue to discuss the future of the Arctic. Attended by over 2000 people from 60 countries each year, political figures, environmental experts, business leaders and scientists gather to raise global awareness of this region.
Alongside the assembly, the Arctic Circle organizes smaller forums around the world, to focus on specific environments and facilitate further discussion. For more information, visit: http://www.arcticcircle.org/
About Cosmetic 360
Cosmetic 360 is an innovative-centered trade fair for the cosmetic industry. The conference brings together professionals and industry representatives from all over the world. All facets of the cosmetic industry are represented at the conference including raw materials, formulation, packaging, testing and analysis, finished products, and distribution. More information on the conference can be found at https://www.cosmetic-360.com/en/
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, please contact:
Christopher Hopton, CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in Business, Medical Marijuana, News Home, Sirona Biochem
CROP’s California Harvest in and ‘first Revenue’ Close
Momentum Public Relations
Press Release: October 11, 2018
CROP Infrastructure Corp. (CSE: CROP) (OTC: CRXPF) (“CROP”) announced today its California tenant has now finished harvesting the entire 30,000 square feet of production area.
The crop tally stands at approximately 2,100 pounds consisting of ~300 lbs of dried flower, ~1,100 lbs which is currently drying, and an additional ~700 lbs of lower tier production for extracts, etc. In line with CROP’s standardized growing protocols, the greenhouses have now been repopulated and the plants are already in flower for a further Q4 harvest.
CROP Infrastructure CEO, Michael Yorke, stated: “CROP is now only steps away from first revenue as the tenant’s sales cycle has been initiated. Of particular significance too, we can also report that the tenant’s temporary cannabis licenses have now been converted to a permanent California state license. CROP looks forward to having its California operations rapidly becoming profitable.”
The cannabis will now be trimmed and packaged to the specifications of the various distributors the tenant is contracting with. The crop strains are 707 OG, Forbidden Fruit, Green Crack, Birthday Cake, and Girl Scout Cookie. In addition, the tenant has added a new sought-after strain, Insane OG.
The company is awaiting construction permits to build out 12 proprietary light supplemented greenhouses totaling 44,000 sq. feet.
About CROP
CROP Infrastructure Corp. is publicly listed on the Canadian Securities Exchange and trades under the symbol “CROP” and in the US under the symbol “CRXPF”. CROP is primarily engaged in the business of investing, constructing, owning and leasing greenhouse projects as part of the provision of turnkey real estate solutions for lease-to-licensed cannabis producers and processors offering best-in-class operations. The Company’s portfolio of projects includes cultivation properties in California, two in Washington State, a 1,000-acre Nevada Cannabis farm, an 1,865 acre CBD farm, extraction in Nevada with international focuses in Jamaica and Italy and a joint venture on West Hollywood and San Bernardino dispensary applications.
CROP has developed a portfolio of assets including Canna Drink, a cannabis infused functional beverage, US and Italian distribution rights to over 55 cannabis topical products and a portfolio of 16 Cannabis brands.
Company Contact
Michael Yorke – CEO, Director
E-mail: info@cropcorp.com
Website: www.cropcorp.com
Phone: (604) 484-4206
- Published in Business, CROP Infrastructure, Medical Marijuana, News Home